Abstract:New drugs are needed to shorten and simplify treatment of tuberculosis caused by Mycobacterium tuberculosis . Metabolic pathways that M . tuberculosis requires for growth or survival during infection represent potential targets for anti-tubercular drug development. Genes and metabolic pathways essential for M . tuberculosis growth in standard laboratory culture conditions have been defined by genome-wide genetic screens. However, whether M . tuberculosis requires these essential genes during infection has not been comprehensively explored because mutant strains cannot be generated using standard methods. Here we show that M . tuberculosis requires the phenylalanine (Phe) and de novo purine and thiamine biosynthetic pathways for mammalian infection. We used a defined collection of M . tuberculosis transposon (Tn) mutants in essential genes, which we generated using a custom nutrient-rich medium, and transposon sequencing (Tn-seq) to identify multiple central metabolic pathways required for fitness in a mouse infection model. We confirmed by individual retesting and complementation that mutations in pheA (Phe biosynthesis) or purF (purine and thiamine biosynthesis) cause death of M . tuberculosis in the absence of nutrient supplementation in vitro and strong attenuation in infected mice. Our findings show that Tn-seq with defined Tn mutant pools can be used to identify M . tuberculosis genes required during mouse lung infection. Our results also demonstrate that M . tuberculosis requires Phe and purine/thiamine biosynthesis for survival in the host, implicating these metabolic pathways as prime targets for the development of new antibiotics to combat tuberculosis. Mycobacterium tuberculosis causes more than 10 million new cases of active tuberculosis (TB) disease and ~1.3 million deaths worldwide each year. Individuals with active TB must take a combination of four antibiotics for a minimum of 6–9 months to cure the infection. New anti-tubercular drugs are needed to simplify TB treatment and combat drug resistance. Here, we describe a novel collection of M . tuberculosis mutants lacking metabolic pathways essential for growth in standard laboratory conditions. Using these mutants, a mouse infection model, and deep sequencing we identified those metabolic pathways that M . tuberculosis also requires during infection. We find that M . tuberculosis mutants that cannot synthesize purine nucleotides, riboflavin, or certain amino acids are unable to grow in mice. We also find that mutant strains which cannot synthesize purine nucleotides or the amino acid phenylalanine die rapidly in laboratory cultures without nutrient supplementation, suggesting that new drugs targeting these pathways would kill M . tuberculosis . Overall, our work reveals multiple metabolic pathways that M . tuberculosis requires during infection, which could be pursued as new targets for development of anti-tubercular drugs.

pH dependent direct sulfhydrylation pathway is required for pathogenesis of

Mycobacterium tuberculosis metC (Rv3340) derived hydrogen sulphide conferring bacteria stress survival.

Kupyaphores are zinc homeostatic metallophores required for colonization of Mycobacterium tuberculosis

Depletion of essential mycobacterial gene glmM reduces pathogen survival and induces host-protective immune responses against tuberculosis

Divergent downstream biosynthetic pathways are supported by L-cysteine synthases of Mycobacterium tuberculosis

Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development

Opposing reactions in coenzyme A metabolism sensitize Mycobacterium tuberculosis to enzyme inhibition

The M. tuberculosis Rv1523 Methyltransferase Promotes Drug Resistance Through Methylation-Mediated Cell Wall Remodeling and Modulates Macrophages Immune Responses

The Mycobactin Biosynthesis Pathway: A Prospective Therapeutic Target in the Battle against Tuberculosis

Transposon sequencing reveals metabolic pathways essential for Mycobacterium tuberculosis infection

The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development

Phosphoglucomutase A mediated regulation of carbon flux is essential for antibiotic and disease persistence in Mycobacterium tuberculosis

Genome mining of Mycobacterium tuberculosis: targeting SufD as a novel drug candidate through in silico characterization and inhibitor screening

Chemical genetic interactions elucidate pathways controlling tuberculosis antibiotic efficacy during infection

S-Adenosylmethionine-responsive cystathionine β-synthase modulates sulfur metabolism and redox balance in Mycobacterium tuberculosis

Targeting Mycobacterium tuberculosis pH-driven adaptation

Targeted suppression of MEP pathway genes DXS, IspD and IspF to explore the mycobacterial metabolism and survival

Modulation of riboflavin biosynthesis and utilization in mycobacteria

Mycobacterium tuberculosis H2S Functions as a Sink to Modulate Central Metabolism, Bioenergetics, and Drug Susceptibility

Inducing vulnerability to InhA inhibition restores isoniazid susceptibility in drug-resistant Mycobacterium tuberculosis

Methionine Aminopeptidases from Mycobacterium tuberculosis as Novel Antimycobacterial Targets